ESSA Pharma Shares Are Trading Lower After Oppenheimer Downgraded the Stock From Outperform to Perform. Piper Sandler Downgraded Its Rating From Overweight to Neutral and Cut Its Price Target From $15 to $2.
ESSA Pharma Shares Are Trading Lower After Oppenheimer Downgraded the Stock From Outperform to Perform. Piper Sandler Downgraded Its Rating From Overweight to Neutral and Cut Its Price Target From $15 to $2.
essa pharma股價下跌，Oppenheimer將股票評級從Outperform調降至Perform。派傑投資將其評級從Overweight降級爲中立，並將目標價從15美元減至2美元。
ESSA Pharma Shares Are Trading Lower After Oppenheimer Downgraded the Stock From Outperform to Perform. Piper Sandler Downgraded Its Rating From Overweight to Neutral and Cut Its Price Target From $15 to $2.
essa pharma股價下跌，Oppenheimer將股票評級從Outperform調降至Perform。派傑投資將其評級從Overweight降級爲中立，並將目標價從15美元減至2美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間